Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials

Table 1 Characteristic of studies included in the meta-analysis

Study	Intervention	Control	No. of patient	Gender (female)	Mean age, y	Co-morbidity of CVDs	Co-morbidity of diabetes	Total cholesterol (mmol/L)	GFR (ml/min/1.73 m²)	Creatinine (mg/dL)	LDL lowing	Follow-up (month)	Jadad score
CARE(2003)³⁴	Pravastatin	Placebo	1711	369(21.6%)	64.3	AMI	NR	5.40	NR	1.26	NR	58.9	3
HPS(2003)^27†	Simvastatin	Vitamins/Placebo	1329	NR	NR	NR	NR	NR	NR	NR	NR	57.0	2
PPP(2004)²³	Pravastatin	Placebo	16824	1840(10.9%)	59.5	NR	NR	6.05	68.5	1.18	51.1%	60.0	3
PREVENDIT (2004)²⁴	Pravastatin	Fosinopril/Placebo	864	303(35.1%)	51.3	NR	3%	5.80	NR	1.02	24.4%	46.0	4
LIPIS(2005)³¹	Pravastatin	Placebo	310	102(33%)	69.0	PCI	NR	5.17	NR	1.33	NR	46.0	2
4S Study (2007)²⁸	Simvastatin	Placebo	2314	618(26.7%)	60.5	CHD	NR	6.75	65.2	1.5	38.0%	65.5	2
ATIC(2007)²⁵	Pravastatin	Placebo	93	40(43.0%)	53.0	No history of AOD	Excluded diabetes	5.60	33.5	2.32	26.1%	18.0	5
TNT(2008)³⁰	Atorvastatin	Atorvastatin	3107	1005(32.3%)	65.5	CHD	NR	4.55	52.9	NR	18.0%	60.0	2
AFCAPS (2009)	Lovastatin	Placebo	304	65(21.4%)	62.0	No history of CVD	Excluded diabetes	5.74	53.0	1.4	27.0%	64.0	3
ALLIANCE (2009)²⁹	Atorvastatin	Usual Care	579	134(23.1%)	65.2	CHD	NR	5.89	51.2	1.5	34.5%	54.3	2
MEGA(2009)²⁶	Pravastatin	Diet	7196	NR	NR	No history of CVD	NR	NR	65.0	NR	18.5%	64.0	2
JUPITER (2010)³³	Rosuvastatin	Placebo	3267	2129(65.2%)	70.0	NR	Excluded diabetes	4.89	56.0	NR	52.0%	22.8	2
SHARP (2011)¹⁴	Simvastatin	Placebo	6247	NR	NR	No history of MI	NR	NR	NR	NR	68.0%	58.8	5

Abbreviations: CVD cardiovascular disease, LDL low density lipoprotein, AMI acute myocardial infarction, PCI percutaneous coronary intervention, CHD coronary heart disease, AOD arterial occlusive disease, MI myocardial infarction, NR not reported, GFR Glomerular filtration rate. ^†: only a subgroup of the total study was included.

ISSN: 1471-2261